ADCNF
Adicon Holdings Limited, an investment holding company, provides medical testing services in the People's Republic of China. The company offers medical diagnostic testing services; testing services for research and development projects; and research and clinical trial services. It also engages in the trading of medical testing equipment; and sale of medical products. The company was founded in 20… Read more
ADCNF (ADCNF) - Net Assets
Latest net assets as of June 2025: $1.77 Billion USD
Based on the latest financial reports, ADCNF (ADCNF) has net assets worth $1.77 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.51 Billion) and total liabilities ($2.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.77 Billion |
| % of Total Assets | 39.31% |
| Annual Growth Rate | 14.32% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 93.52 |
ADCNF - Net Assets Trend (2021–2025)
This chart illustrates how ADCNF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ADCNF (2021–2025)
The table below shows the annual net assets of ADCNF from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.77 Billion | -2.95% |
| 2024-06-30 | $1.83 Billion | +198.63% |
| 2023-06-30 | $612.34 Million | -28.20% |
| 2022-06-30 | $852.85 Million | -17.93% |
| 2021-06-30 | $1.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ADCNF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $1.65 Billion | 100.00% |
| Total Equity | $1.65 Billion | 100.00% |
ADCNF Competitors by Market Cap
The table below lists competitors of ADCNF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Oceanking Development Co Ltd
SHG:603213
|
$172.01 Million |
|
Xinjiang Haoyuan Natural Gas Co Ltd
SHE:002700
|
$172.04 Million |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
$172.07 Million |
|
SUZUKI
MU:SKI
|
$172.07 Million |
|
Chunbo Co. Ltd
KQ:278280
|
$171.96 Million |
|
Capital Futures Corp
TW:6024
|
$171.88 Million |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
$171.85 Million |
|
Idorsia Ltd
PINK:IDRSF
|
$171.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADCNF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,708,071,000 to 1,648,085,000, a change of -59,986,000 (-3.5%).
- Net income of 47,014,000 contributed positively to equity growth.
- Share repurchases of 112,838,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $47.01 Million | +2.85% |
| Share Repurchases | $112.84 Million | -6.85% |
| Other Changes | $6.37 Million | +0.39% |
| Total Change | $- | -3.51% |
Book Value vs Market Value Analysis
This analysis compares ADCNF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.46x to 0.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $1.42 | $0.65 | x |
| 2022-06-30 | $1.11 | $0.65 | x |
| 2023-06-30 | $0.71 | $0.65 | x |
| 2024-06-30 | $2.35 | $0.65 | x |
| 2025-06-30 | $2.31 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ADCNF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.61%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 2.84x
- Recent ROE (2.85%) is below the historical average (43.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 27.74% | 10.36% | 1.01x | 2.66x | $181.69 Million |
| 2022 | 39.23% | 9.34% | 1.09x | 3.87x | $235.12 Million |
| 2023 | 133.27% | 14.01% | 1.00x | 9.50x | $629.71 Million |
| 2024 | 13.75% | 7.12% | 0.72x | 2.67x | $64.08 Million |
| 2025 | 2.85% | 1.61% | 0.62x | 2.84x | $-117.79 Million |
Industry Comparison
This section compares ADCNF's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $818,386,618
- Average return on equity (ROE) among peers: -25.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADCNF (ADCNF) | $1.77 Billion | 27.74% | 1.54x | $172.01 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |